Reported efficacy outcomes (HRs [95% CI] vs warfarin) of the respective NOACs in the phase 3 trials [1]–[5] in the intent-to-treat analysis.
收藏Figshare2015-12-02 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Reported_efficacy_outcomes_HRs_95_CI_vs_warfarin_of_the_respective_NOACs_in_the_phase_3_trials_1_5_in_the_intent_to_treat_analysis_/1051365
下载链接
链接失效反馈官方服务：
资源简介：
AP, apixaban; CI, confidence interval; DE, dabigatran etexilate; EDOX, edoxaban; HR, hazard ratio; RIVA, rivaroxaban. Note. Bold font marks results where the 95% CIs do not cross or touch 1.00.*Dose with most pronounced efficacy result. †Includes ischemic strokes only.
创建时间：
2015-12-02
